NCM 106 Module 9F: Nursing Care of Clients with Drugs for Special Conditions

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/34

flashcard set

Earn XP

Description and Tags

Comprehensive vocabulary flashcards covering obstetric tocolytics, labor inducers, hormonal contraceptives, ophthalmic antiglaucoma agents, and otic medications from NCM 106 Module 9F.

35 Terms

1
New cards

Iron Products (PO Dosing in Pregnancy)

Oral iron supplements (such as ferrous sulfate, ferrous gluconate, and ferrous fumarate) indicated at a dose of 15 mg15\,\text{mg} once daily in the first trimester, and 27 mg27\,\text{mg} once daily during the last two trimesters to prevent and treat iron deficiency anemia.

2
New cards

Liquid Iron Administration

A formulation that causes discoloration of teeth; interventions include diluting the liquid, having the client drink it with a straw, and administering it on an empty stomach with water, juice, or Vitamin C to enhance absorption.

3
New cards

Folic Acid (Vitamin B9)

A water-soluble B vitamin whose deficiency early in pregnancy can cause spontaneous abortion, premature birth, low birth weight, placental abruption, and neural tube defects (NTDs); clients with a prior pregnancy affected by an NTD require a higher prophylactic dose of 4000 mcg4000\,\text{mcg} starting 11 to 33 months prior to conception.

4
New cards

Preterm Labor (PTL)

The occurrence of cervical changes and regular uterine contractions occurring between 2020 and 3737 weeks of gestation, representing the leading cause of newborn and infant mortality.

5
New cards

Tocolytics

Off-label medications that interrupt or inhibit uterine contractions to buy time for fetal maturation, allow antenatal corticosteroid administration, and permit maternal transport to an appropriate care facility.

6
New cards

Terbutaline

A beta-sympathomimetic tocolytic bearing a Black Box Warning against prolonged use or prevention of PTL; adverse maternal effects include tachycardia, tremors, hyperglycemia, and hypokalemia; contraindicated in cardiac disease, poorly controlled hyperthyroidism, and diabetes mellitus.

7
New cards

Magnesium Sulfate (Tocolytic)

A calcium antagonist and central nervous system depressant that relaxes uterine smooth muscle through calcium displacement, given as an off-label tocolytic with a 44 to 6 g6\,\text{g} IV loading dose over 2020 to 30 minutes30\,\text{minutes}, followed by 11 to 2 g/h2\,\text{g/h} for up to 48 hours48\,\text{hours}.

8
New cards

Magnesium Toxicity Danger Signs

Clinical warning signs during magnesium sulfate therapy comprising loss of deep tendon reflexes (DTRs), maternal confusion, decreased fetal heart rate (FHR), and neonatal respiratory depression or hypotonia.

9
New cards

Calcium Gluconate

The specific antidote for magnesium sulfate toxicity, administered at a dose of 1 g1\,\text{g} IV over 3 minutes3\,\text{minutes}.

10
New cards

Therapeutic Serum Magnesium Level

The target serum concentration during magnesium sulfate tocolytic therapy, defined as 44 to 7 mg/dL7\,\text{mg/dL}.

11
New cards

Dinoprostone Cervical Gel

A naturally occurring prostaglandin containing 0.5 mg0.5\,\text{mg} dinoprostone in 2.5 mL2.5\,\text{mL} used intracervically to ripen an unfavorable cervix; requires recumbency for 1515 to 30 minutes30\,\text{minutes} after administration and a waiting period of 66 to 12 hours12\,\text{hours} before initiating oxytocin.

12
New cards

Oxytocin

A uterine stimulant used for labor induction, augmentation, and control of postpartum hemorrhage; prepared by diluting 10 units10\,\text{units} in 1000 mL1000\,\text{mL} lactated Ringer's (10 milliunits/mL10\,\text{milliunits/mL}) and administered as a secondary IV piggyback to prevent tachysystole and water intoxication.

13
New cards

Methylergonovine Maleate

An ergot alkaloid that stimulates smooth muscle to produce tetanic contractions, used exclusively after delivery to control postpartum hemorrhage and promote involution; contraindicated in gestational hypertension and peripheral vascular disease.

14
New cards

Ergotism

Toxicity caused by ergot alkaloids characterized by numbness, cold extremities, severe limb and lower back pain, muscular weakness, seizures, hallucinations, and blood hypercoagulability resulting from intense vasoconstriction.

15
New cards

Combined Hormonal Contraceptives (CHCs)

Contraceptive formulations combining synthetic estrogen (which inhibits ovulation) and progestin (which suppresses the LH surge and thickens cervical mucus) to produce drug-induced anovulatory cycles.

16
New cards

Withdrawal Bleeding

Scheduled monthly bleeding (pseudomenstruation) occurring during the hormone-free interval of combined hormonal contraceptive therapy, mimicking a regular 2828-day menstrual period.

17
New cards

Breakthrough Bleeding

Unscheduled or unexpected bleeding or spotting occurring while actively taking hormonal contraceptive medications.

18
New cards

Missed CHC Protocol (1 Tablet)

Take the missed tablet as soon as remembered and take the next tablet at the regularly scheduled time without requiring backup contraception.

19
New cards

Missed CHC Protocol (2 Tablets)

Take 22 tablets as soon as remembered and 22 tablets the following day, accompanied by a back-up contraceptive method for the remainder of the cycle.

20
New cards

Missed CHC Protocol (3 Tablets)

Discontinue the pack to permit withdrawal bleeding, begin a new pack 7 days7\,\text{days} after the last tablet was taken, and use an additional contraceptive method until new tablets have been taken for 77 consecutive days.

21
New cards

Transdermal Contraceptive Patch

A weekly combined hormonal system delivering ethinyl estradiol (20 mcg20\,\text{mcg} or 35 mcg35\,\text{mcg}) and norelgestromin (150 mcg150\,\text{mcg}) every 24 hours24\,\text{hours}, applied for 33 consecutive weeks followed by 11 patch-free week; ineffective in women weighing 198 lbs198\,\text{lbs} or more.

22
New cards

Transvaginal Contraceptive Ring

A flexible, colorless indwelling ring releasing 15 mcg15\,\text{mcg} ethinyl estradiol and 120 mcg120\,\text{mcg} etonogestrel daily; retained for 3 weeks3\,\text{weeks} and removed for 1 week1\,\text{week}; requires backup contraception for 7 days7\,\text{days} if expelled for greater than 3 hours3\,\text{hours}.

23
New cards

Progestin-Only Pills (POPs)

Oral contraceptives containing 0.35 mg0.35\,\text{mg} norethindrone taken continuously every single day within a strict 33-hour window; a delayed dose requires back-up contraception for 48 hours48\,\text{hours}.

24
New cards

Depot Medroxyprogesterone Acetate (DMPA)

A long-acting injectable progestin administered at 150 mg/mL150\,\text{mg/mL} deep intramuscularly into the ventral gluteus or deltoid every 1111 to 13 weeks13\,\text{weeks}; injection site must not be massaged.

25
New cards

Etonogestrel Subdermal Implant

A single, radiopaque rod containing 68 mg68\,\text{mg} etonogestrel placed in the inner upper non-dominant arm providing contraception for up to 3 years3\,\text{years}.

26
New cards

Prostaglandin Analogues (Ophthalmic)

First-line antiglaucoma agents (e.g., latanoprost, bimatoprost, travoprost, tafluprost) administered at bedtime that reduce intraocular pressure by improving uveoscleral and trabecular outflow; can cause irreversible brown iris pigmentation and hypertrichosis of eyelashes.

27
New cards

Timolol (Ophthalmic)

A nonselective beta-adrenergic blocker that decreases aqueous humor production without altering pupil size; contraindicated in patients with asthma, chronic obstructive pulmonary disease (COPD), bradycardia, heart failure, and advanced AV block.

28
New cards

Alpha-Adrenergic Agonists (Ophthalmic)

Sympathomimetic agents (such as apraclonidine and brimonidine) that act on the ciliary body to decrease aqueous humor production and increase outflow; contraindicated concurrently with monoamine oxidase inhibitor (MAOI) therapy.

29
New cards

Carbonic Anhydrase Inhibitors (CAIs)

Sulfonamide-derived medications (topical dorzolamide, brinzolamide; systemic acetazolamide) that decrease aqueous humor formation; contraindicated in individuals with sulfonamide allergies and capable of inducing hyperuricemia or gout.

30
New cards

Mydriatics and Cycloplegics

Diagnostic ophthalmic agents where mydriatics dilate pupils and cycloplegics paralyze accommodation; both are strictly contraindicated in angle-closure glaucoma due to the risk of precipitating an acute rise in intraocular pressure.

31
New cards

Dapiprazole

An ophthalmic alpha-adrenergic receptor antagonist utilized specifically to reverse diagnostic mydriasis induced by phenylephrine.

32
New cards

Ophthalmic Administration Interval Rule

The nursing standard requiring eyedrops to be instilled prior to eye ointments, with a mandatory waiting period of at least 5 minutes5\,\text{minutes} between the administration of different ophthalmic medications.

33
New cards

Acute Otitis Media (AOM)

An infection of the middle ear most commonly seen in children under 2 years2\,\text{years} of age, characterized by otalgia, a bulging tympanic membrane, and eustachian tube dysfunction; treated first-line with high-dose amoxicillin (8080 to 90 mg/kg90\,\text{mg/kg}).

34
New cards

Otitis Externa (OE)

An infection of the external auditory canal commonly termed swimmer's ear, predominantly caused by Pseudomonas aeruginosa or Staphylococcus aureus, treated with topical fluoroquinolones such as ciprofloxacin otic 0.2%0.2\% or ofloxacin otic 0.3%0.3\%.

35
New cards

Cerumenolytics

Topical otic formulations used to soften or remove earwax; categorized into water-based agents that hydrate and disintegrate dried cerumen, and oil-based preparations that lubricate and soften without disintegration.